ALSO NOTED: Medarex therapy gains fast track; J&J suspends trial; and much more...

> The FDA has put Medarex's MDX-010 skin cancer therapy on the agency's fast track. Report

> Johnson & Johnson says that problems experienced by a vendor in distributing drugs for the clinical trials of golimumab for RA will force it to temporarily suspend enrollment in some Phase III studies. J&J says it will resolve the problem quickly. J&J is co-developing the drug with Schering-Plough. Report

> India's Dr. Reddy's is developing a combinational therapy for heart disease. Report

> Basilea Pharmaceutical is exercising its co-promotional option with Cilag on an investigational antibiotic. Report

> WuXi PharmaTech and Merck have agreed to extend and expand an agreement through which WuXi provides a variety of chemistry-related R&D services. Release

> Researcher touts new work on insulin-producing cells. Report

> Scientists find potential Achilles heel in flu virus. Report

> Stem cell transplant may be successful against Parkinson's. Report

And Finally… A string of deaths this year has led some researchers to wonder if marathons are too much of a good thing for runners. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.